IRADIMED CORPORATION — 2021 Form 10-K Summary
Business context and reporting period
For the fiscal year ended December 31, 2021, IRadimed developed, manufactured and sold MRI-compatible medical devices, accessories, disposables and services. Its main products are the MRidium IV infusion pump system and the 3880 patient vital signs monitoring system. Sales are primarily to hospitals and acute care facilities, through a direct U.S. sales force and international distributors. The filing is an annual report, not a standalone fourth-quarter filing.
Financial performance and liquidity
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | $41.8 million | $31.7 million |
| Gross profit / margin | $32.0 million / 76.6% | $23.6 million / 74.3% |
| Operating income (loss) / margin | $9.8 million / 23.5% | $(0.8) million / (2.4)% |
| Net income | $9.3 million | $1.4 million |
| Diluted earnings per share | $0.74 | $0.11 |
| Cash provided by operating activities | $11.3 million | $5.8 million |
- Revenue increased 31.8%. U.S. revenue rose 36.4% to $33.5 million; international revenue rose 16.3% to $8.4 million. Device revenue grew 41.6% to $27.1 million, with growth in both pump and monitor sales.
- Year-end cash and cash equivalents were $62.0 million, with $0.5 million in investments. Working capital was $69.4 million and stockholders’ equity was $72.2 million. The company reported no borrowings; liabilities included $2.5 million in operating lease liabilities.
- Management stated liquidity was expected to fund projected requirements for at least 12 months from issuance of the financial statements. Contractual obligations totaled $8.7 million, including purchase obligations of $5.6 million and operating lease obligations of $3.1 million.
- Fourth-quarter 2021 revenue was $11.9 million, operating income was $3.1 million and net income was $3.9 million. In fourth-quarter 2020, revenue was $8.5 million, operating income was $0.7 million and net income was $0.6 million.
Material changes versus prior comparable periods
- 2021 revenue and profitability rebounded from 2020, when revenue had fallen 17.7% from 2019 and the company recorded an operating loss. 2021 revenue remained above 2019’s $38.5 million.
- Gross margin improved by 2.3 percentage points from 2020, attributed mainly to favorable overhead variances and higher average selling prices. Operating expenses fell to $22.2 million from $24.3 million, including lower general and administrative costs.
- 2020 general and administrative expense included $3.2 million related to the former CEO, including $2.7 million for separation costs. The 2020 tax benefit also included a CARES Act net operating loss carryback benefit; the 2021 tax provision was $0.5 million.
- Year-end cash and investments increased to $62.5 million from $52.0 million in 2020. Operating cash flow increased by $5.5 million.
Outlook, commentary, risks and unusual items
- The filing refers readers to a 2022 outlook, but the supplied filing text does not provide clear numerical revenue or earnings guidance.
- Management described continued uncertainty from COVID-19, including potential effects on hospital access, procedure volumes, customer budgets, collections, supply availability and operations. Selling cycles had lengthened beyond their historical three-to-six-month range.
- Key risks include reliance on two principal product lines, a single Florida manufacturing facility, sole-source suppliers for critical components—including the infusion-pump motor—and extensive medical-device regulation. The company also depends on international distributors and faces competition in patient monitoring.
- The company disclosed a prior FDA warning letter affecting pump distribution that it says was resolved. It also identified evolving EU medical-device requirements and potential recertification costs and delays as risks.
- On February 7, 2022, the board declared a special $1.00-per-share dividend, paid February 24, totaling approximately $12.6 million. This post-year-end payment reduced cash after December 31, 2021.
- The company leases its headquarters and manufacturing facility from an entity controlled by founder and CEO Roger Susi; 2021 rent paid was approximately $462,000. The filing reported no pending litigation expected to materially affect operations and no off-balance-sheet arrangements.
Important facts for investors to verify
- Whether the 2021 sales recovery and improved margins continue, particularly given longer sales cycles and hospital spending priorities.
- How much recurring disposable, service and warranty revenue is generated by the growing installed base, and whether device sales translate into sustained cash generation.
- Whether the company can maintain supply and production capacity despite sole-source components and broader supply-chain risks.
- Progress and cost of regulatory compliance and recertification, especially for EU market access.
- The cash balance and capital-allocation plans after the $12.6 million special dividend, including any future dividends or share repurchases.
- Terms and governance oversight of the related-party facility lease, and the company’s ongoing dependence on its founder and CEO.